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Abstract: It is suggested that tumour stromal myofibroblasts exert an unfavourable effect on the biology of breast cancer. We
are aware of only a single study which examined relationships between manifestation of myofibroblasts in the stroma of breast
cancer and clinicopathological data of the patients. The present study was aimed at estimation of the effect exerted by
myofibroblasts present in the tumour stroma on principal pathological parameters and on expression of Ki67 , P53 and HER-2
proteins in the group of the most frequent breast cancers, the ductal cancers. In paraffin sections of 60 ductal breast cancers
(20 cases in G1, 20 in G2 and 20 in G3), immunohistochemical reactions were performed to detect expression of smooth muscle
actin (SMA) in order to visualize myofibroblasts, Ki67, P53 and HER-2. The studies demonstrated that the most numerous
myofibroblasts were present in G3 cases and they were the least frequent in G1 cases (P=0.02). Positive correlations were
observed between the presence of myofibroblasts in tumour stroma and expression of Ki67 and HER-2 in breast cancer cells
in the entire group (P <0.001 and P=0.001, respectively), in G2 cases (P=0.003 and P=0.03) and in G3 cases (P=0.01 and
P=0.03). Considering that the higher grade, Ki67 and HER-2 are thought to represent unfavourable prognostic factors, the elevated
content of myofibroblasts in tumour stroma is probably typical for cases with worse prognosis. (www.cm-uj.krakow.pl/FHC)
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Introduction
Breast cancer is the most common malignant tumour of
females in the western world, being responsible for
about 32% of the estimated new female cancer cases.
The incidence of breast cancer remains high, and the
clinical courses are highly variable. For years, a growing
incidence of the disease has been documented and the
risk of dying of breast cancer continues to increase in
consecutive cohorts of generations [5]. Therefore, in
numerous centres intense efforts develop to detect new
prognostic factors which would permit to intensify the
therapy in high risk cases. Moreover, such prognostic
factors might provide an interesting topic for studies on
new therapeutic approaches. Conventional prognostic
and predictive markers for breast cancer are stage of the
advancement (nodal status, tumour size and presence of
the metastases), tumour grade and tumour size [4]. Ex-
pression of receptors for female sex hormones [10] and
HER-2 is also of importance [4]. In addition, expression
of the proliferation-associated antigen, Ki67 and of the
suppressor protein, P53 are frequently estimated in order
to establish the dynamics of tumour growth [12]. Signific-
ance of several other proteins and of their expression in
breast cancer cells continues to stimulate studies world-
wide. Until now, however, only expression of receptors for
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female sex hormones and of HER-2 have found appli-
cation in a routine diagnosis of breast cancer [4]. 
In recent years, numerous publications have de-
scribed effects of tumour-associated tissues on the
dynamics of neoplastic disease. Invasion of tumour
cells is slowed down by myoepithelial cells and basal
membranes [9]. The immune system has been found
to protect the body from neoplastic cells. On the other
hand, tumour cells produce, i.a. metalloproteinases
and growth factors which may facilitate invasion of
tumour cells. Tumour-associated vessels provide path-
way for spread of tumour cells [6]. The interactions
between tumour cells and stromal myofibroblasts re-
main, however, poorly recognized. Myofibroblasts pro-
duce several factors which may stimulate proliferation
of cancer cells and facilitate their infiltration. They have
been found to secrete, i.a., insulin-like growth factor-2
(IGF-2) and hepatocyte growth factor (HGF) [2]. Recog-
nition of relationships between myofibroblasts and breast
cancer cells may facilitate definition of new prognostic
factors and provide targets for novel therapeutic ap-
proaches.
The present study was aimed at examination of rela-
tionships between the presence of myofibroblasts in
tumour stroma and principal pathological parameters as
well as expression of Ki67, P53 and HER-2 proteins in
a group of most frequent breast cancers, the ductal
cancers.
Materials and methods
Patients. Immunocytochemical analysis was performed retrospec-
tively on tissue samples collected for routine diagnostic purposes.
Based on histology (invasive ductal breast cancer) and grade (equal
groups for each grade), 60 patients with primary invasive breast
cancer diagnosed in the years 1999 to 2000 in the Lower Silesian
Centre of Oncology (Wroclaw, Poland) were included in the study.
The mean age of the patients was 55.62 years ± 9.86 SD (age range:
43 to 72 years). Every grade (G1, G2 and G3) was represented by 20
cases. In 34 patients stage 2a, in 22 patients stage 2b and in 4 patients
stage 3 of the tumour was diagnosed. Fragments sampled from the
studied tumours were fixed in 10% buffered formalin and embedded
in paraffin. In every case, hematoxylin and eosin stained sections
were examined by two pathologists. The stage of tumours was
assessed according to TNM classification system [8]. Tumour grade
was estimated according to Bloom-Richardson, according to the
modification of Elston and Ellis [3] (Table 1).
Immunohistochemistry. Formalin-fixed, paraffin-embedded sec-
tions (4 µm) were mounted on Superfrost slides (Menzel Gläser,
Germany), dewaxed with xylene, and gradually rehydrated. Activity
of endogenous peroxidase was blocked by 30 min incubation in 1%
H2O2. The studied sections were boiled 15 minutes in Target Retrie-
val Solution (DakoCytomation, Poland) , in a microwave oven at 250
W. Then, immunohistochemical reactions were performed using
monoclonal antibodies detecting smooth muscle actin (SMA, clone
1A4, DakoCytomation, Poland) diluted 1:200, Ki67 (clone MIB-1,
DakoCytomation, Poland) diluted 1:100, P53 (clone DO-7, Dako-
Cytomation, Poland) diluted 1:100 and polyclonal anti-HER-2 anti-
bodies (DakoCytomation, Poland) diluted 1:350. The antibodies
were diluted in the Antibody Diluent, Background Reducing (Dako-
Cytomation, Denmark). The sections were incubated with antibodies
for 1 h at room temperature. Subsequent incubations included bioti-
nylated secondary antibodies (15 min, room temperature) and strep-
tavidin-biotinylated peroxidase complex (15 min, room temperature)
(LSAB+, HRP, DakoCytomation, Denmark). NovaRed (Vector La-
boratories, UK) was used as chromogen (10 min, at room tempera-
ture). All sections were counterstained with Meyers hematoxylin.
In every case, control reactions were included, in which specific
antibody was substituted by the Primary Mouse Negative Control
(DakoCytomation, Denmark).
Scoring of immunostaining results. Myofibroblasts visualized by
SMA expression were assessed semiquantitatively with the use of a
simplified scale based on the percentage of myofibroblasts in the
population of tumour stromal cells (0 - no myofibroblasts, 1 - <10%
of myofibroblasts in tumour stroma, 2 - 10-30% of myofibroblasts
in tumour stroma, 3 - >30% of myofibroblasts in tumour stroma).
Expression of P53 and Ki67 was quantitated by calculating the
percentage values of immunopositive cells. For evaluation of HER-2
reactivity, the DakoCytomation scoring system was used (0 = nega-
tive; + = partial membranous; ++ = complete membranous, weak;
+++ = complete membranous, strong). The intensity of immunohis-
tochemical reactions was assessed independently by two patholog-
ists; in doubtful cases a re-evaluation was performed using a
double-headed microscope. In each case we analyzed 6 microscopic
fields at × 200 magnification.
Statistical analysis. Statistical analysis of the obtained results was
conducted using Statistica 98 PL software (Statsoft, Poland). At the
first stage of the calculations, the presence of myofibroblasts was
compared in individual groups (G1, G2, G3) using Kruskal-Wallis
rank ANOVA test. Subsequently, relationships were examined (em-
ploying the same test) between the presence of myofibroblasts and
expression of the studied variables in all groups together (G1 to G3)
and in each group (G1, G2 and G3). 
Results
Immunostaining
Detection of SMA yielded reaction of a cytoplasmic
localization and of variable intensity in individual cases.
SMA was present in myofibroblasts (Fig. 1), myoepithe-
 Table 1. Characteristics of patients and tumours
Characteristics No. (%)
Patients 60 (100)
Age (mean 55.62
years ± 9.86 SD)
≤50  5 (8.3)
50-60 32 (53.3)
>60 23 (38.3)
Tumour grade
1 20 (33.3)
2 20 (33.3)
3 20 (33.3)
Tumour stage
2a 34 (56.7)
2b 22 (36.7)
3  4 (6.6)
Histology
Invasive ductal
breast cancer
60 (100)
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lial cells and in muscles of blood vessels. According to
the applied scale, the mean manifestation of myofibro-
blasts amounted to 2.01±0.69.
Application of antibodies against P53 or Ki67
yielded in tumour cells colour reaction of nuclear local-
ization and of a variable intensity in individual cases.
The mean percentage of P53-positive and Ki67-positive
breast cancer cells was 40.71±26.69 and 28.56±17.7,
respectively.
In the case of HER-2, membrane reaction was ob-
tained of various intensity in individual cases, localized
in the tumour cells. The mean reaction intensity in
DakoCytomation 0-3 score was 1.84±0.74.
Relationships between the presence 
of myofibroblasts and histopathological parameters
The analysis performed using the Kruskal-Wallis rank
ANOVA test demonstrated no relationships between the
presence of myofibroblasts in tumour stroma and stage
or age of the studied patients (P=0.67 and P=0.54,
respectively). Nevertheless, a significant positive corre-
lation was disclosed between the presence of myofibro-
blasts in tumour stroma and grade of the studied tumors
(P=0.02, Fig. 2). Cases of higher grade manifested
augmented content of myofibroblasts in tumour stroma.
Relationships between the presence 
of myofibroblasts and expression 
of P53, Ki67 and HER-2
Using also the Kruskal-Wallis rank ANOVA test, rela-
tionships were examined between the presence of
myofibroblasts in the tumours and expression of P53,
Ki67 and HER-2 in individual grades (G1, G2 and G3)
or in the entire group (G1-3). The test demonstrated no
significant relationships in the G1 group (P>0.05, Table 2).
In none of the examined groups could a relationship be
disclosed between the presence of myofibroblasts in the
Fig. 1. Immunohistochemical localization of smooth muscle actin in
breast cancer tumors. A. Reaction in individual myofibroblasts
(<10%, score: 1) in tumour stroma (gray arrow) and in blood vessel
(black arrow). × 200. B. Reaction in numerous myofibroblasts
(>30%, score: 3) in tumour stroma (gray arrow). × 200. C. Reaction
in numerous myofibroblasts (>30%, score: 3) in tumour stroma (gray
arrow). × 400.
Fig. 2. The presence of myofibroblasts in tumour stroma related to
tumour grade (Kruskal-Wallis rank ANOVA test). Myofibroblasts
are the most numerous in stroma of G3 tumours.
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tumour stroma and expression of P53 in cancer cells
(P>0.05, Table 2). However, in groups G2 (Fig. 3), G3
(Fig. 4) and in the entire studied material (G1-3, Fig. 5)
a significant positive correlation was noted between the
presence of myofibroblasts in tumour stroma and ex-
pressions of Ki67 and HER-2 in cancer cells (P<0.05,
Table 2). In cases with the highest content of myofibro-
blasts in tumour stroma, the most pronounced express-
ion of  Ki67 and HER-2 was also observed in cancer
cells.
Discussion
The present study demonstrates the significance of
myofibroblast presence in tumour stroma, as detected by
smooth muscle actin (SMA) expression [1]. We have
documented that myofibroblasts are present in tumour
stroma in a proportion of breast cancers. This result has
confirmed results of other authors. Yazhou et al. [11]
investigated the relation between the presence of myofi-
broblasts in tumour stroma and clinico-pathological
variables in the breast cancer patients. In the present
study we have shown that cases of higher grade demon-
strate higher content of myofibroblasts in tumour stro-
ma. Similarly to Yazhou et al. [11], we have noted no
relationship between manifestation of myofibroblasts
and age of the studied patients. Also, in line with the data
of the cited authors, the content of myofibroblasts in
tumour stroma has not been related to stage of the
studied tumours. 
We have also examined potential relationships be-
tween manifestation of myofibroblasts in tumour stroma
and expression of Ki67 , P53 and HER-2 in breast cancer
cells. Until now, only the relationship between myofi-
broblast content and expression of Ki67 in breast cancer
cells has been investigated [11] and no significant rela-
tionship has been detected. In the present study, how-
ever, cases with higher content of myofibroblasts in
tumour stroma have been found to contain higher pro-
portions of cancer cells with Ki67 expression. Since
myofibroblasts, both in  tumours and in healing pro-
cesses, produce numerous growth factors [2], we sug-
gest that myofibroblast-released growth factors might
stimulate proliferation of breast cancer cells. 
In this study, no relationship has been documented
between the presence of myofibroblasts in tumour stro-
ma and expression of P53 in breast cancer cells. How-
ever, cases with higher content of myofibroblasts have
Fig. 4. In G3group, cases with the highest content of myofibroblasts
exhibit: A. Higher content of cancer cells with Ki67 expression; B.
Higher expression of HER-2 in cancer cells (Kruskal-Wallis rank
ANOVA test).
Fig. 3. In G2 group, cases with the highest content of myofibroblasts
exhibit: A. Higher content of cancer cells with Ki67 expression; B.
Higher expression of HER-2 w in cancer cells (Kruskal-Wallis rank
ANOVA test).
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been found to exhibit more intense expression of HER-2
in breast cancer cells. Myofibroblasts may secrete in-
sulin-like growth factor-2 (IGF-2) and hepatocyte
growth factor (HGF) [7]. They represent ligands for
receptors of the Epidermal Growth Factor Receptor
group, which includes, i.a., HER-2. The ligands, most
probably in a paracrine way, stimulate expression of
HER-2 in breast cancer cells. Since HER-2 represents
one of the best recognised negative prognostic factors
[4] we suggest that the presence of myofibroblasts in
tumour stroma may be linked to unfavourable prognosis
in breast cancer patients. 
In summary, the present investigations have demon-
strated that breast cancer cases with higher content of
myofibroblasts in tumour stroma are characterised by
higher grade of the tumour, more intense proliferation
of neoplastic cells and more intense expression of HER-
2 in cancer cells. To our knowledge, this paper describes
for the first time a positive correlation between the
presence of myofibroblasts in tumour stroma and intens-
ity of Ki67 and HER-2 expression. Taking into account
that higher grade, Ki67 and HER-2 are regarded to
represent negative prognostic indicators, the intensified
content of myofibroblasts in tumour stroma may be
typical for cases with a worse prognosis. The signific-
ance of myofibroblast presence in the stroma of breast
cancers should be investigated in detail, in order to detect
new prognostic indicators and novel targets for thera-
peutic approaches.
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